Indian researchers have achieved a major leap in precision oncology with OncoMark an advanced AI framework that delves into the hidden molecular mechanisms powering cancer cells. Unlike conventional diagnostics relying on tumor size, spread, or visible traits, OncoMark quantifies the activity of all 10 “hallmarks of cancer” core biological processes like evading immune detection, promoting metastasis, and resisting therapy that transform normal cells into malignant ones.

Trained on transcriptomic data from 3.1 million single cells across 14 cancer types, the neural multi-task learning model creates detailed molecular profiles of tumors. It predicts hallmark probabilities with exceptional precision: over 99% accuracy in internal validation and consistently above 96% across multiple independent real-world datasets, including large cohorts like TCGA and MET500.

Key strengths include visualizing how hallmark patterns intensify with cancer stage progression and distinguishing biologically aggressive tumors that appear similar under traditional TNM staging. This deeper insight described as “reading the mind of cancer” empowers clinicians to select therapies targeting dominant hallmarks, forecast resistance, and tailor treatments for better outcomes.

The open-source tool, detailed in Communications Biology (October 2025), includes a web interface for easy integration into research and clinical workflows. Future expansions target blood cancers, rare malignancies, and bedside decision support.

This indigenous innovation addresses a critical gap existing tools often focus on subsets of hallmarks or pathways, leaving oncologists without comprehensive molecular views. By enabling hallmark-driven personalization, OncoMark could reduce overtreatment, improve survival rates, and accelerate India’s role in global precision oncology.